HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Normanno, N Articles by Pinto, A Search for Related Content PubMed PubMed Citation Articles by Normanno, N Articles by Pinto, A

¹ Cell Biology and Preclinical Models, INT-Fondazione Pascale, Via Mariano Semmola, 80131 Naples, Italy
² Pathology Unit, INT-Fondazione Pascale, Naples, Italy
³ Hematology Oncology Unit, INT-Fondazione Pascale, Naples, Italy
⁴ Clinical and Experimental Haematology Research Unit, Centro di Riferimento Oncologico, Aviano (PN), Italy
⁵ Department of Cellular and Molecular Biology and Pathology, Federico II University, Naples, Italy

(Requests for offprints should be addressed to N Normanno; Email: nicnorm{at}yahoo.com)

Significant relief of bone pain in patients with bone metastases was observed in a clinical trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in breast cancer. Osteoclast activation and differentiation are regulated by bone marrow stromal cells (BMSC), a heterogeneous cell compartment that comprehends undifferentiated mesenchymal stem cells (MSC) and their specialized progeny. In this regard, we found that human primary BMSCs express immunoreactive EGFR. Expression of EGFR mRNA and protein was also demonstrated in two human, continuous MSC-like cell lines, HDS-1 and HDS-2 cells. Treatment of HDS cells with EGF produced a significant increase in the levels of activated EGFR which was not observed in the presence of gefitinib. A significant reduction in the basal levels of activation of the EGFR and of Akt was observed in HDS cells following treatment with gefitinib. Treatment of HDS cells with gefitinib produced a significant reduction in the levels of secreted macrophage colony-stimulating factor (M-CSF) and cell-associated receptor activator of NF-B ligand (RANKL) in both cell lines, as assessed by using specific ELISA and Western blotting techniques. Finally, the ability to sustain the differentiation of pre-osteoclasts of conditioned medium from gefitinib-treated HDS cells was reduced by approximately 45% as compared with untreated HDS cells. These data have demonstrated for the first time that the EGFR regulates the ability of BMSCs to induce osteoclast differentiation and strongly support clinical trials of gefitinib in breast cancer patients with bone disease.

This article has been cited by other articles:

				P. O. Prada, E. R. Ropelle, R. H. Mourao, C. T. de Souza, J. R. Pauli, D. E. Cintra, A. Schenka, S. A. Rocco, R. Rittner, K. G. Franchini, et al. EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice Diabetes, December 1, 2009; 58(12): 2910 - 2919. [Abstract] [Full Text] [PDF]

				J. L. Gilmore, R. M. Gonterman, K. Menon, G. Lorch, D. J. Riese II, A. Robling, and J. Foley Reconstitution of Amphiregulin-Epidermal Growth Factor Receptor Signaling in Lung Squamous Cell Carcinomas Activates PTHrP Gene Expression and Contributes to Cancer-Mediated Diseases of the Bone Mol. Cancer Res., October 1, 2009; 7(10): 1714 - 1728. [Abstract] [Full Text] [PDF]

				N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone Target-based therapies in breast cancer: current status and future perspectives Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702. [Abstract] [Full Text] [PDF]

				X. Lu, Q. Wang, G. Hu, C. Van Poznak, M. Fleisher, M. Reiss, J. Massague, and Y. Kang ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis Genes & Dev., August 15, 2009; 23(16): 1882 - 1894. [Abstract] [Full Text] [PDF]

				L. A Kingsley, P. G J Fournier, J. M Chirgwin, and T. A Guise Molecular Biology of Bone Metastasis Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 443 - 457. [Abstract] [Full Text] [PDF]

				L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF]

				J. Zhu, X. Jia, G. Xiao, Y. Kang, N. C. Partridge, and L. Qin IMPLICATIONS FOR OSTEOLYTIC BONE METASTASES J. Biol. Chem., September 14, 2007; 282(37): 26656 - 26664. [Abstract] [Full Text] [PDF]

				C. J. Xian Roles of Epidermal Growth Factor Family in the Regulation of Postnatal Somatic Growth Endocr. Rev., May 1, 2007; 28(3): 284 - 296. [Abstract] [Full Text] [PDF]

				N. Normanno and W. J Gullick Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr. Relat. Cancer, March 1, 2006; 13(1): 3 - 6. [Abstract] [Full Text] [PDF]

				A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210. [Abstract] [Full Text] [PDF]